Die Marktgröße für erbliche Krebstests wird bis 2027 schätzungsweise 9.840,52 Millionen US-Dollar erreichen, verglichen mit 3.967,74 Millionen US-Dollar im Jahr 2018; Es wird erwartet, dass sie zwischen 2019 und 2027 mit einer jährlichen Wachstumsrate von 11,1 % wächst.
Ein erblicher Krebs ist jeder Krebs, der durch eine vererbte Genmutation verursacht wird. Es ist bekannt, dass schädliche Varianten in einigen Genen mit einem erhöhten Krebsrisiko verbunden sind. Gentests helfen bei der Einschätzung des Risikos einer Person, im Laufe ihres Lebens an Krebs zu erkranken. Dies kann durch die Suche nach Mutationen in Genen, Chromosomen oder Proteinen erfolgen. Für einige Krebsarten stehen Gentests zur Verfügung. Dazu gehören Brustkrebs, Eierstockkrebs, Dickdarmkrebs, Schilddrüsenkrebs, Prostatakrebs, Bauchspeicheldrüsenkrebs, Melanom, Sarkom, Nierenkrebs und Magenkrebs.
Der Markt für Tests auf erblichen Krebs Diese Trends sind auf die zunehmende Konzentration auf die Forschung und Entwicklung von Gentests zur Analyse der Korrelation des Krebses mit der genetischen Sequenz, die zunehmende Prävalenz von erblichem Krebs und die steigende Nachfrage nach DNA-Testkits zurückzuführen. Strenge Vorschriften für die Krebsdiagnostik können jedoch das Marktwachstum behindern.
Strategische Einblicke
Lukrative Regionen für den Markt für erbliche Krebstests
Markteinblicke< /h3> Zunehmende Prävalenz von erblich bedingtem Krebs
Krebs ist eine genetische Erkrankung, die durch bestimmte Variationen in Genen verursacht wird, die die Zellfunktion steuern und insbesondere deren Wachstum und Replikation beeinflussen. Erbliche genetische Mutationen sind die Ursache für etwa 510 % aller Krebserkrankungen. Die Forscher haben Mutationen in bestimmten Genen mit mehr als 50 erblichen Krebssyndromen in Verbindung gebracht, die Einzelpersonen bei der Entwicklung bestimmter Krebsarten beeinträchtigen. Nach Angaben der Weltgesundheitsorganisation verursachte Krebs im Jahr 2018 weltweit etwa 9,6 Millionen Todesfälle. Darüber hinaus würden nach der Prognose des National Cancer Institute im Jahr 2018 in den USA etwa 1.735.350 neue Krebsfälle diagnostiziert. Die weltweit zunehmende Prävalenz von Brustkrebs gibt Anlass zu großer Sorge. Nach Angaben der Weltgesundheitsorganisation wurden im Jahr 2018 weltweit etwa 2,09 Millionen Fälle von Brustkrebs gemeldet. Allerdings wurden laut breastcancer.org im Jahr 2018 in den USA über 3,1 Millionen Frauen mit Brustkrebs in der Vorgeschichte gemeldet.
Darüber hinaus stehen etwa 510 % der Brustkrebserkrankungen im Zusammenhang mit mutierten Genen, die von den Eltern geerbt wurden. Die Variationen in den BRCA1- und BRCA2-Genen sind weit verbreitet. Frauen mit einer BRCA1-Mutation haben ein Lebenszeitrisiko von etwa 72 %, an Brustkrebs zu erkranken, während Frauen mit der BRCA2-Mutation ein gleiches Risiko von etwa 69 % haben. Darüber hinaus steht APAC vor dem Problem der zunehmenden Krebsprävalenz. China, Japan, Indien, Taiwan, Südkorea, Malaysia, Singapur, Thailand, die Philippinen, Sri Lanka, Vietnam, Indonesien, die Mongolei, Laos und Kambodscha sind die 15 Länder mit der höchsten Krebsinzidenz. Nach Angaben des National Institute of Cancer Prevention and Research (NICPR) verursachte Krebs im Jahr 2018 in Indien 784.821 Todesfälle. Daher treibt die zunehmende Prävalenz von Krebs das stetige Wachstum von erblichem Krebs voran und treibt damit das Wachstum des Marktes für Tests auf erblichen Krebs voran.
Diagnosetypbasierte Einblicke
Der globale Markt für Tests auf erblichen Krebs Je nach Diagnosetyp wird die Diagnose in Biopsie und Bildgebung unterteilt. Im Jahr 2018 hatte der Bereich Biopsie einen größeren Anteil. Für den Bereich Bildgebung wird jedoch im Zeitraum 20192027 ein schnelleres Wachstum erwartet. Es wird erwartet, dass das Biopsiesegment aufgrund der steigenden Prävalenz von Krebs, der steigenden Nachfrage nach minimalinvasiven Operationen sowie Initiativen von Regierungen und globalen Gesundheitsorganisationen wachsen wird.
Technologiebasierte Erkenntnisse
The Der weltweite Markt für Tests auf erblich bedingte Krebserkrankungen ist technologiebasiert in Sequenzierung, PCR und Microarray unterteilt. Das Sequenzierungssegment war 2018 das größte Technologie-Untersegment und dürfte im Zeitraum 20192027 weiterhin ein deutliches Wachstum verzeichnen. Es wird erwartet, dass das Sequenzierungssegment aufgrund der Zuweisung von Mitteln durch verschiedene Regierungsbehörden und der Verwendung von NGS bei der Sequenzierung und der gezielten Sequenzierung für verschiedene Zwecke, wie z. B. die Erkennung von erblichem Krebs, wachsen wird.
Endbenutzerbasierte Erkenntnisse< /h3>
Der globale Markt für Tests auf erblich bedingte Krebserkrankungen ist je nach Endbenutzer in Diagnosezentren, Krankenhäuser und Kliniken unterteilt. Es wird erwartet, dass die Diagnosezentren im Prognosezeitraum das höchste Wachstum verzeichnen werden. Der größte Anteil entfiel jedoch im Jahr 2018 auf das Krankenhaussegment und es wird erwartet, dass sich dieser Trend im Prognosezeitraum fortsetzt. Es wird erwartet, dass das Segment der Diagnosezentren aufgrund der genauen Diagnose und des geringeren Risikos einer Trial-and-Error-Behandlung wachsen wird. Gentests helfen bei der Abschätzung des Risikos, im Laufe des Lebens an Krebs zu erkranken, indem sie nach Mutationen in Genen, Chromosomen oder Proteinen suchen.
Produkteinführungen und -zulassungen sind gängige Strategien von Unternehmen, um ihre globale Präsenz und ihr Produktportfolio zu erweitern. Darüber hinaus konzentrieren sich die Marktteilnehmer für Erbkrebstests auf die Partnerschaftsstrategie, um ihren Kundenkreis zu vergrößern, was ihnen wiederum ermöglicht, ihren Markennamen auf der ganzen Welt zu behaupten. Es wird erwartet, dass der Marktanteil bei Tests auf erblich bedingte Krebserkrankungen mit der Entwicklung neuer innovativer Produkte durch Marktteilnehmer florieren wird. Einige auf dem Markt tätige Akteure sind Hologic Inc.; Koninklijke Philips NV; Quest Diagnostics Incorporated; Myriad Genetics, Inc.; Ambry Genetics; NeoGenomic Laboratories; Anwalt; Cancer Genetics Inc.; Invitae Corporation; Myogenes; Strand Life Sciences Pvt. GmbH.; Pathway Genomics Corporation; und CENTOGENE AG.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
In terms of end user, the global hereditary cancer testing market is segmented into diagnostic centers, hospital, and clinics. Among the above 4 segments, the diagnostic centers segment held the largest market share in 2018.
The hospital segment is estimated to grow at the fastest rate during the forecast period.
Problems in accessing whole genomic data for early detection is the major factor hindering the market growth.
The List of Companies
- Hologic Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Cancer Genetics Inc.
- Invitae Corporation
- Myogenes
- Strand Life Sciences Pvt. Ltd.
- Pathway Genomics Corporation
- CENTOGENE AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Sep 2019
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Sep 2019
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Sep 2019
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Sep 2019
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)